Get the Stockscreener App
8.45
0.72%
0.06
After Hours:
8.60
0.15
+1.78%
Arvinas Inc stock is traded at $8.45, with a volume of 616.59K.
It is up +0.72% in the last 24 hours and up +13.88% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$8.39
Open:
$8.37
24h Volume:
616.59K
Relative Volume:
0.72
Market Cap:
$545.20M
Revenue:
$89.40M
Net Income/Loss:
$-221.30M
P/E Ratio:
-2.5949
EPS:
-3.2564
Net Cash Flow:
$-256.90M
1W Performance:
+1.93%
1M Performance:
+13.88%
6M Performance:
-28.57%
1Y Performance:
+6.29%
1-Day Range:
$8.10
$8.56
1-Week Range:
$8.01
$8.67
52-Week Range:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
8.45 | 536.17M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Form 4 Arvinas Inc For: 26 June By Investing.com - Investing.com South Africa
Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4 - Stock Titan
Arvinas (ARVN) director receives RSU and stock option grants in equity award - Stock Titan
Arvinas (ARVN) director Briggs Morrison granted RSUs and stock options - Stock Titan
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
Arvinas (ARVN) director receives new RSU and stock option awards - Stock Titan
Director Linda Bain receives RSUs and stock options at Arvinas (ARVN) - Stock Titan
Arvinas Inc (ARVN) Institutional Confidence - TradingKey
Arvinas, Inc. (NASDAQ: ARVN) Files Form 8-K: Key Company Details, Stock Info, and Compliance Disclosures (June 24, 2026) – Minichart - Minichart
Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arvinas, Inc. Actuals & Estimates (NASDAQ:ARVN) - TradingView
Arvinas Shareholders Back Directors, Pay and Auditor Choices - TipRanks
Arvinas (NASDAQ: ARVN) investors back directors, pay and auditor - Stock Titan
ARVN Forecast — Price Target — Prediction for 2027 - TradingView
Arvinas CFO Andrew Saik sells $46,473 in company stock - Investing.com UK
Form 4 Arvinas Inc For: 24 June By Investing.com - Investing.com Nigeria
Arvinas CFO Andrew Saik sells $46,473 in company stock By Investing.com - Investing.com Australia
ARVINAS (ARVN) CFO auto-sells shares to cover RSU tax withholding - Stock Titan
(ARVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
ARVN: All voting items passed at the virtual meeting, with no shareholder questions submitted - TradingView
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas Inc (ARVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arvinas, Inc. (ARVN) reports Q1 loss, misses revenue estimates - MSN
Form 144 Arvinas Inc For: 23 June By Investing.com - Investing.com South Africa
Arvinas (NASDAQ: ARVN) to settle 5,846 vested RSU shares on 06/24/2026 - Stock Titan
Arvinas Announces Chief Medical Officer Leadership Transition - The Globe and Mail
[8-K] ARVINAS, INC. Reports Material Event - Stock Titan
ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (ARVN) CSO has shares sold automatically to cover RSU tax withholding - Stock Titan
Arvinas, Inc. $ARVN Stock Holdings Lifted by Armistice Capital LLC - MarketBeat
Arvinas Inc (ARVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment - The Globe and Mail
Arvinas Inc (ARVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arvinas Inc (ARVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arvinas Inc (ARVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arvinas Inc (ARVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arvinas (NASDAQ: ARVN) insider sells 2,642 shares; May sale of 9,657 noted - Stock Titan
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal - MSN
Pfizer trades up with Rigel’s Veppanu deal done - TechStock²
According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a - Bitget
Arvinas, Pfizer receive $70M upfront as Rigel deal for VEPPANU clears HSR - TradingView
Arvinas (NASDAQ: ARVN) secures $70M VEPPANU payment and major milestones - Stock Titan
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):